NO20063963L - Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav - Google Patents

Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav

Info

Publication number
NO20063963L
NO20063963L NO20063963A NO20063963A NO20063963L NO 20063963 L NO20063963 L NO 20063963L NO 20063963 A NO20063963 A NO 20063963A NO 20063963 A NO20063963 A NO 20063963A NO 20063963 L NO20063963 L NO 20063963L
Authority
NO
Norway
Prior art keywords
multiparticular
desmethylvenlafaxine salts
desmethylvenlafaxine
salts
odv
Prior art date
Application number
NO20063963A
Other languages
English (en)
Inventor
Mahdi Bakir Fawzi
Syed Muzafar Shah
Christopher Richard Diorio
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20063963L publication Critical patent/NO20063963L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Multipartikulært 0-desmetylvenlafeksin (ODV)-suksinat eller -formiat. Fremgangsmåter for å behandle depresjon og å redusere de gasfrointestinale bivirkninger av ODV beskrives også.
NO20063963A 2004-02-06 2006-09-05 Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav NO20063963L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54238404P 2004-02-06 2004-02-06
PCT/US2005/002215 WO2005077340A1 (en) 2004-02-06 2005-01-25 Multiparticulate o-desmethylvenlafaxine salts and uses thereof

Publications (1)

Publication Number Publication Date
NO20063963L true NO20063963L (no) 2006-09-05

Family

ID=34860300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063963A NO20063963L (no) 2004-02-06 2006-09-05 Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav

Country Status (21)

Country Link
US (1) US20050175698A1 (no)
EP (2) EP2052717A1 (no)
JP (1) JP2007520553A (no)
KR (1) KR20060132891A (no)
CN (1) CN1917860A (no)
AR (1) AR050230A1 (no)
AU (1) AU2005212166A1 (no)
BR (1) BRPI0507372A (no)
CA (1) CA2554559A1 (no)
CR (1) CR8535A (no)
EC (1) ECSP066827A (no)
IL (1) IL177052A0 (no)
NO (1) NO20063963L (no)
PA (1) PA8622601A1 (no)
PE (1) PE20050771A1 (no)
RU (1) RU2006127437A (no)
SG (1) SG149894A1 (no)
SV (1) SV2005002008A (no)
TW (1) TW200528092A (no)
WO (1) WO2005077340A1 (no)
ZA (1) ZA200606526B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
EP1864967A1 (en) 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
EP1832288B1 (en) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
AU2006229869A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
CA2614209A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7595340B2 (en) * 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
AU2006270315A1 (en) * 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
PE20070247A1 (es) * 2005-07-15 2007-04-11 Wyeth Corp Derivados dimetilamino como agentes inhibidores de la recaptacion doble de serotonina y norepinefrina con alta selectividad
US7687520B2 (en) * 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
WO2009009665A2 (en) * 2007-07-12 2009-01-15 Dr. Reddy's Laboratories, Ltd. O-desmethylvenlafaxine
US20100330172A1 (en) * 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
EP2212275A2 (en) * 2007-10-22 2010-08-04 Actavis Group PTC EHF Solid forms of (±)-o-desmethylvenlafaxine salts
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
BR112013025766A2 (pt) 2011-04-12 2016-12-20 Lupin Ltd composições farmacêuticas de liberação modificada de desvenlafaxina
US20150086628A1 (en) * 2012-05-03 2015-03-26 Cipla Limited Antiretroviral composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081496A (en) * 1959-10-15 1963-03-19 John F Moore Method of forming flexible sheets of cured foamed rubber
AT294000B (de) * 1965-01-11 1971-11-10 Diersch & Schroeder Verfahren zur Herstellung von Teppichen oder Läufern
US3885257A (en) * 1972-10-30 1975-05-27 Evans Ronald J P Pressure controlled resilient supporting structure
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4603445A (en) * 1983-09-09 1986-08-05 Span-America Medical Systems, Inc. Support pad and method of manufacture
US5099627A (en) * 1990-09-28 1992-03-31 Benjamin Obdyke Incorporated Ventilated roof construction and method
US5203703A (en) * 1991-08-27 1993-04-20 Schneiderman Marc J Deglutition training method and apparatus
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6162309A (en) * 1998-04-21 2000-12-19 Burlington Industries, Inc. Reinforced foam backed carpet
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6863972B2 (en) * 2001-01-09 2005-03-08 Crane Plastics Company Llc Synthetic wood component having a foamed polymer backing
EP1864967A1 (en) 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
US20030152741A1 (en) * 2002-02-05 2003-08-14 Robbins Jeffrey L. Patterned polyurethane foam and a process for the production of tufted goods with patterned foam backing
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
NZ537142A (en) 2002-06-10 2008-01-31 Wyeth Corp Novel formate salt of O-desmethyl-venlafaxine
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物

Also Published As

Publication number Publication date
AU2005212166A1 (en) 2005-08-25
CR8535A (es) 2006-12-07
EP2052717A1 (en) 2009-04-29
SV2005002008A (es) 2005-11-04
AR050230A1 (es) 2006-10-11
BRPI0507372A (pt) 2007-07-10
JP2007520553A (ja) 2007-07-26
KR20060132891A (ko) 2006-12-22
CN1917860A (zh) 2007-02-21
US20050175698A1 (en) 2005-08-11
TW200528092A (en) 2005-09-01
EP1711167A1 (en) 2006-10-18
SG149894A1 (en) 2009-02-27
ECSP066827A (es) 2006-11-24
ZA200606526B (en) 2010-03-31
PE20050771A1 (es) 2005-11-15
IL177052A0 (en) 2006-12-10
CA2554559A1 (en) 2005-08-25
WO2005077340A1 (en) 2005-08-25
RU2006127437A (ru) 2008-03-20
PA8622601A1 (es) 2005-10-28

Similar Documents

Publication Publication Date Title
NO20063963L (no) Multipartikulaere 0-desmetylvenlafaksinsalter og anvendelser derav
IL273422A (en) Methods and systems for extracorporeal organ treatment
ATE474617T1 (de) Medizinproduktsysteme
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
CY1117721T1 (el) Κυτταρα προελευσης αμνιακου υγρου
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
TW200700433A (en) Acylated glp-1 compounds
NO20081042L (no) PPAR aktive forbindelser
NO20082082L (no) Modulatorer for ATP-bindingskassettstransportere
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
NO20076003L (no) TGF-beta 1 spesifikke antistoffer
MX2010001657A (es) Reguladores de mmp-9 y usos de los mismos.
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2007021989A3 (en) Interlayers comprising an ultraviolet curable layer
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
DE602005015102D1 (de) Wässrige dispersionen von silikon-polyether-blockcopolymeren
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
TW200722897A (en) Projection partitioning and aligning
ATE383384T1 (de) Selbstemulgierende wässrige polyurethandispersionen
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
WO2005110479A3 (en) Treatments for pancreatic cancer
WO2004067564A3 (en) Compositions against cancer antigen liv-1 and uses thereof
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
NO20051605L (no) Reparajon av DNA-mutagen skade

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application